FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer

Posted by Food and Drug Administration--Press Releases on Friday Aug 26, 2011 Under News

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

Be Sociable, Share!

Comments are closed.